Abstract:Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease in Caucasians caused by pathogenic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (CFTR). Significant small molecule therapeutic advances over the past two decades have been made to target the defective CFTR protein and enhance its function. To address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in CF, two biomolecular activities are required, namely, correctors to increase the amount of properly folded F508delCFTR levels at the cell surface and potentiators to allow the effective opening, i.e., function of the F508delCFTR channel. Combined, these activities enhance chloride ion transport yielding improved hydration of the lung surface and subsequent restoration of mucociliary clearance. To enhance clinical benefits to CF patients, a complementary triple combination therapy consisting of two corrector molecules, type 1 (C1) and type 2, with additive mechanisms along with a potentiator are being investigated in the clinic for maximum restoration of mutated CFTR function. We report the identification and in vitro biologic characterization of ABBV-2222/GLPG2222 (4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid),—a novel, potent, and orally bioavailable C1 corrector developed by AbbVie-Galapagos and currently in clinical trials—which exhibits substantial improvements over the existing C1 correctors. This includes improvements in potency and drug-drug interaction (DDI) compared with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (VX-809, Lumacaftor) and improvements in potency and efficacy compared with 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide (VX-661, Tezacaftor). ABBV-2222/GLPG2222 exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 value <10 nM.SIGNIFICANCE STATEMENTTo address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in cystic fibrosis, AbbVie-Galapagos has developed ABBV-2222/GLPG2222, a novel, potent, and orally bioavailable C1 corrector of this protein. ABBV-2222/GLPG2222, which is currently in clinical trials, exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR and substantial improvements over the existing C1 correctors.

Curcumin and Genistein: the Combined Effects on Disease-associated CFTR Mutants and Their Clinical Implications

Curcumin and Genistein Additively Potentiate G551D-CFTR

Effects of Genistein and Curcumin on Non ATP-Hydrolytic CFTR Mutants

Effects Of Aromatic Carboxylic Acids On Genistein- And Curcumin- Potentiated G551d-Cftr

Pharmacokinetics and Pharmacodynamics of the Combination of Rhein and Curcumin in the Treatment of Chronic Kidney Disease in Rats

An Ensemble Docking Study

Curcumin Inhibits Transforming Growth Factor-Beta Activity Via Inhibition of Smad Signaling in HK-2 Cells.

Therapeutic potential of phytochemicals for cystic fibrosis

Silibinins and curcumin as promising ligands against mutant cystic fibrosis transmembrane regulator protein

A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

Clinical studies with curcumin.

Functional Consequences of CFTR Interactions in Cystic Fibrosis

Effects of curcumin on ion channels and transporters.

Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1

Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

Evaluation of Autophagy Inducers in Epithelial Cells Carrying the ΔF508 Mutation of the Cystic Fibrosis Transmembrane Conductance Regulator CFTR.

Structure-guided combination therapy to potently improve the function of mutant CFTRs

Advancing Gastrointestinal Health: Curcumin's Efficacy and Nanopreparations

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

Genistein Restores Functional Interactions Between ΔF508-CFTR and ENaC in Xenopus Oocytes

Identification of novel natural compounds against CFTR p.Gly628Arg pathogenic variant